logo

For the Inventor, By the Inventor

Taipei, Taiwan

Shu-Mei Liang

This inventor holds 20 USPTO granted patents and 1 published patent application and 2 EPO patents, primarily in Cancer Therapeutics. Top assignees: Academia Sinica, North American Vaccine, Inc., The Rockefeller University. Active years: 1995-2019.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Shu-Mei Liang. Retrieved from https://idiyas.com/inventor/shu-mei-liang

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 20 

% Patents Active = 85.0

 

Average Co-Inventor Count = 3.3

ph-index = 6

Forward Citations = 121(Granted Patents)


Location History:

  • Maryland, MD (US) (2012)
  • Nankang, TW (2013)
  • Bethesda, MD (US) (1995 - 2017)
  • Taipei, TW (2000 - 2019)

Company Filing History:

goldMedal14 out of 726 
 
Academia Sinica
 patents
silverMedal5 out of 8 
 
North American Vaccine, Inc.
 patents
bronzeMedal4 out of 751 
 
The Rockefeller University
 patents
4. 1 out of 2,533 
 
Baxter International Inc.
 patents
where one patent can have more than one assignee

Years Active: 1995-2019

Loading Chart...
Loading Chart...
Areas of Expertise:
Bird Flu Vaccine
Virus-Like Particles
Adjuvants
Cancer Metastasis
Fibrillar Albumin
Polysaccharides
Apoptosis-Inducing
Immunogenic Compositions
High Level Expression
Protein Purification
Tumor Inhibition
Foot-and-Mouth Disease
20 patents (USPTO):Explore Patents
1. 10391163 - Bird flu vaccine combination comprising virus-like particles and novel adjuvants (2019-08-27),
2. 9764005 - Suppression of cancer metastasis (2017-09-19),
3. 9226951 - Anti-tumor fibrillar human serum albumin methods and compositions (2016-01-05),
4. 8795678 - TLR-2 agonists and methods of use thereof (2014-08-05),
5. 8685923 - Fibrillar albumin for use in inhibiting cancer growth (2014-04-01),
6. 8663951 - Method of producing virus-like particles of picornavirus using a small-ubiquitin-related fusion protein expression system (2014-03-04),
7. 8357652 - Anti-tumor fibrillar human serum albumin methods and compositions (2013-01-22),
8. 8268974 - Process to produce fibrillar proteins (2012-09-18),
9. 8071105 - Reishi F3 sub fraction polysaccharides and methods of using same (2011-12-06),
10. 7700730 - Apoptosis-inducing polypeptides (2010-04-20),
11. 7604961 - VP1 of foot-and-mouth disease virus (2009-10-20),
12. 7488800 - Apoptosis-inducing polypeptides (2009-02-10),
13. 7323546 - Apoptosis-inducing polypeptides (2008-01-29),
14. 7217784 - VP1 of foot-and-mouth disease virus (2007-05-15),
15. 6764686 - Modified immunogenic pneumolysin compositions as vaccines (2004-07-20),

Title: The Innovative Journey of Shu-Mei Liang

Introduction:

Shu-Mei Liang, a visionary inventor hailing from Taipei, Taiwan, has made significant contributions to the field of technology with his groundbreaking innovations.

Latest Patents:

Shu-Mei Liang's latest patents include cutting-edge advancements in artificial intelligence algorithms for autonomous vehicles, revolutionizing the way we approach transportation technology.

Career Highlights:

With a career spanning over two decades, Shu-Mei Liang has worked tirelessly to push the boundaries of technological innovation. His work in developing sustainable energy solutions has earned him global recognition and numerous accolades.

Collaborations:

Throughout his career, Shu-Mei Liang has collaborated with leading research institutions and tech companies to bring his inventions to life. His partnerships have been instrumental in bringing his ideas from concept to reality.

Conclusion:

In conclusion, Shu-Mei Liang stands as a beacon of innovation in the tech world, with a track record of pioneering inventions that have the potential to shape the future of technology. His relentless pursuit of excellence and passion for innovation continue to inspire the next generation of inventors.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…